2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0093AR
    Benazepril hydrochloride (Standard) 86541-74-4 98%
    Benazepril hydrochloride (Standard) is the analytical standard of Benazepril hydrochloride. This product is intended for research and analytical applications. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy.
    Benazepril hydrochloride (Standard)
  • HY-B0093AS
    Benazepril-d5 hydrochloride 1279026-26-4 98%
    Benazepril-d5 hydrochloride is deuterium labeled Benazepril hydrochloride. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy.
    Benazepril-d5 hydrochloride
  • HY-B0104S1
    Glimepiride-d4-1 1131981-29-7 99.39%
    Glimepiride-d4-1 is deuterium labeled Glimepiride. Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.
    Glimepiride-d4-1
  • HY-B0104S2
    Glimepiride-d8 2012598-49-9 98%
    Glimepiride-d8 (Glimperide-d8; HOE-490-d8) is deuterium-labeled Glimepiride (HY-B0104).
    Glimepiride-d8
  • HY-B0113AR
    Omeprazole sodium (Standard) 95510-70-6
    Omeprazole (sodium) (Standard) is the analytical standard of Omeprazole (sodium). This product is intended for research and analytical applications. Omeprazole sodium (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects.
    Omeprazole sodium (Standard)
  • HY-B0113S1
    Omeprazole-d3-1 934293-92-2
    Omeprazole-d3-1 is the deuterium labeled Omeprazole. Omeprazole-1 (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole-1 competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole-1 inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole-1 inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole-1 alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole-1 aslo has neuroprotective and antibacterial effects.
    Omeprazole-d3-1
  • HY-B0166S2
    L-Ascorbic acid-13C-1 178101-89-8 99.90%
    L-Ascorbic acid-13C-1 is the 13C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen
    L-Ascorbic acid-13C-1
  • HY-B0166S4
    L-Ascorbic acid-13C-3 98%
    L-Ascorbic acid-13C-3 is the 13C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen
    L-Ascorbic acid-13C-3
  • HY-B0166S5
    L-Ascorbic acid-13C-4 149153-08-2 98%
    L-Ascorbic acid-13C-4 is the 13C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collag
    L-Ascorbic acid-13C-4
  • HY-B0174AR
    Olsalazine (Standard) 15722-48-2 98%
    Olsalazine (Standard) is an orally active prodrug of 5-ASA (HY-15027). Olsalazine (Standard) can inhibit cells proliferation and induce apoptosis. Olsalazine (Standard) can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine (Standard) can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.
    Olsalazine (Standard)
  • HY-B0174AS
    Olsalazine-13C6 98%
    Olsalazine-13C6 is the 13C labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.
    Olsalazine-13C6
  • HY-B0178AR
    Guanidine hydrochloride (Standard) 50-01-1
    Guanidine (hydrochloride) (Standard) is the analytical standard of Guanidine (hydrochloride). This product is intended for research and analytical applications. Guanidine hydrochloride (Guanidinium chloride) a strong chaotrope, is also a strong denaturant of proteins.
    Guanidine hydrochloride (Standard)
  • HY-B0227AR
    Ketoprofen (lysinate) (Standard) 57469-78-0
    Ketoprofen (lysinate) (Standard) is the analytical standard of Ketoprofen (lysinate). This product is intended for research and analytical applications. Ketoprofen (RP-19583) lysinate is a non-steroidal anti-inflammatory agent. Ketoprofen lysinate can inhibit the activity of cyclooxygenase with IC50 values of 2 nM (COX-1) and 26 nM (COX-2). which is potential in the research of inflammation, immunology, and metabolic disease such as obesity.
    Ketoprofen (lysinate) (Standard)
  • HY-B0228S2
    Adenosine-2′-13C 714950-52-4 98%
    Adenosine-2′-13C is the 13C labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiolo
    Adenosine-2′-13C
  • HY-B0228S3
    Adenosine-3′-13C 714950-53-5 99.95%
    Adenosine-3′-13C is the 13C labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiolo
    Adenosine-3′-13C
  • HY-B0228S7
    Adenosine-d1-1 119540-53-3 99.5%
    Adenosine-d-1 is the deuterium labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular phys
    Adenosine-d1-1
  • HY-B0236S1
    6-Aminocaproic acid-d10 461432-51-9 98%
    6-Aminocaproic acid-d10 is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders.
    6-Aminocaproic acid-d10
  • HY-B0252S3
    Hydrochlorothiazide-15N2,13C,d2 2140316-81-8 98%
    Hydrochlorothiazide-15N2,13C,d2 is 15N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect.
    Hydrochlorothiazide-15N2,13C,d2
  • HY-B0283S1
    Acipimox-13C2,15N2 2012598-41-1 98%
    Acipimox-13C2,15N2 (K-9321-13C2,15N2) is 13C- and 15N-labeled Acipimox (HY-B0283).
    Acipimox-13C2,15N2
  • HY-B0285AS
    Amiloride-15N3 hydrochloride 1216796-18-7 98%
    Amiloride-15N3 (hydrochloride) is the 15N labeled Amiloride hydrochloride. Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride hydrochloride is a blocker of polycystin-2 (PC2;TRPP2) channel.
    Amiloride-15N3 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity